Fishing communities in some developing countries severely affected by HIV / AIDS.

Prevalence among fishing communities is higher than for other mobile populations, including members of the military and the lorry driver for available data. According to the report, the work of fishermen spend time away from home, a daily income in a general environment of poverty and the availability access of commercial sex in many fishing ports fueling the spread of HIV. Exposure to water transferred diseases and malaria, increase poor hygiene and limited access to health care and the risk of HIV transmission among fishing communities. ‘Our results indicate that the fishing communities at risk much more than farming communities,’Marcela Villarreal – FAO focal point for HIV / AIDS and director of the organization Gender, Equity and Rural Employment Division – and added, ‘with any kind of profession being away from home being away from home makes people more susceptible to getting infected.

The disease usually begins before the age of 16 and may affect up to 1 child 1000 in 1000 in the United States.. ORENCIA Supplemental Biologics License Application for Juvenile idiopathic arthritis by the FDA for the submission and evaluation AcceptedBristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has approved , for the submission and review of the supplemental Biologics License Application for the treatment of pediatric patients with juvenile idiopathic arthritis , the response to disease-modifying antirheumatic drugs have one or more drugs such as methotrexate, MTX) or tumor necrosis factor antagonist. – This sBLA is based based on data from a double-blind randomized study, which consists of three phases: a four-month open-label lead – treatment period during which all participants received ORENCIA and both clinical response and safety were assessed , a six-month randomized double-blind withdrawal phase, The diseasesponder either ORENCIA or placebo and time given until disease progression flare and evaluated safety were and an open-label phase were given all subscribers ORENCIA term efficacy and safety assess the long – term efficacy and safety .The follow-up period differ among groups. It was far more for the historical the untreated group . Median follow -up time for the contemporary group was 5.1 years for a treated MS patients and 4.0 years for the untreated with MS.

Corresponding author of the JAMA study Helen Tremlett is a professor at UBC and holding the Canada Research Chair in Neuroepidemiology and Multiple Sclerosis at UBC. Said she told the press the study gives patients and physician additional information on the longer-term actions of interferon beta. We know this class of drugs very Translation in reducing the recidivism which may be important to patient has not recommended that patients who evidence medication, but prove this knowledge that longer realistic expectation with respect to the to expected benefits associated with drugs treatment out to the obstruction perspective. .

Other Posts From Category "specialist":

Related Posts